SCHEMBL25367764

SCHEMBL25367764

CS(=O)(=O)Nc1cccc(NC(=O)c2cc(C(=O)Nc3ccccc3Oc3ccccc3)cs2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 1/20 0.49
▸ DHX9 Q08211 1/20 0.45
▸ MAPT P10636 4/20 0.45
▸ MEN1 O00255 4/20 0.43
▸ KMT2A Q03164 4/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ PYGM P11217 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ MAPK1 P28482 2/20 0.43
▸ GAA P10253 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ NLRP3 Q96P20 1/20 0.42
▸ RXFP1 Q9HBX9 1/20 0.42
▸ HPGD P15428 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30543909 1.00 ATM (0.49) ATMDHX9MAPTMEN1KMT2A
SCHEMBL25367472 0.88 MEN1 (0.53) DHX9MAPTMEN1KMT2AALDH1A1
SCHEMBL30543926 0.88 MEN1 (0.53) DHX9MAPTMEN1KMT2AALDH1A1
SCHEMBL25369870 0.88 MRGPRX1 (0.46) DHX9MAPTMEN1KMT2AALDH1A1
SCHEMBL30543946 0.86 DHX9 (0.53) DHX9MAPTMEN1KMT2AALDH1A1
SCHEMBL25368280 0.86 DHX9 (0.53) DHX9MAPTMEN1KMT2AALDH1A1
SCHEMBL30543904 0.84 DHX9 (0.50) DHX9MAPTMEN1KMT2AALDH1A1
SCHEMBL25368623 0.84 DHX9 (0.50) DHX9MAPTMEN1KMT2AALDH1A1
SCHEMBL25368459 0.82 NPC1 (0.52) DHX9MAPTALDH1A1SMN1; SMN2GAA
SCHEMBL30543864 0.82 NPC1 (0.52) DHX9MAPTALDH1A1SMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 — — US claimed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO claimed
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 — — US disclosed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO disclosed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF DHX9, DHX29, DDX39B ATM 4102/4885DHX9 1/4885MAPT 3830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback